Steven T Sizemore
Overview
Explore the profile of Steven T Sizemore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Qiu Z, Fa P, Liu T, Prasad C, Ma S, Hong Z, et al.
Cancer Res
. 2020 Jun;
80(16):3305-3318.
PMID: 32522823
There is currently a lack of precise predictive biomarkers for patient selection in clinical trials of inhibitors targeting replication stress (RS) response proteins ATR and CHK1. The objective of this...
12.
Thies K, Steck S, Knoblaugh S, Sizemore S
J Vis Exp
. 2020 Jun;
(159).
PMID: 32510518
Metastasis, the primary cause of morbidity and mortality for most cancer patients, can be challenging to model preclinically in mice. Few spontaneous metastasis models are available. Thus, the experimental metastasis...
13.
Thies K, Hammer A, Hildreth 3rd B, Steck S, Spehar J, Kladney R, et al.
Cancer Res
. 2020 Apr;
81(3):606-618.
PMID: 32327406
Platelet-derived growth factor receptor-beta (PDGFRβ) is a receptor tyrosine kinase found in cells of mesenchymal origin such as fibroblasts and pericytes. Activation of this receptor is dependent on paracrine ligand...
14.
Roberts M, Sahni J, Schrock M, Piemonte K, Weber-Bonk K, Seachrist D, et al.
Cancer Res
. 2020 Feb;
80(8):1693-1706.
PMID: 32054769
A significant therapeutic challenge for patients with cancer is resistance to chemotherapies such as taxanes. Overexpression of LIN9, a transcriptional regulator of cell-cycle progression, occurs in 65% of patients with...
15.
Wan L, Liu T, Hong Z, Pan Y, Sizemore S, Zhang J, et al.
Breast Cancer Res
. 2019 Dec;
21(1):148.
PMID: 31856858
Background: A role for neural precursor cell-expressed developmentally downregulated gene 4 (NEDD4) in tumorigenesis has been suggested. However, information is lacking on its role in breast tumor biology. The purpose...
16.
Sizemore S, Zhang M, Cho J, Sizemore G, Hurwitz B, Kaur B, et al.
Cell Res
. 2018 Oct;
28(11):1090-1102.
PMID: 30297868
Resistance to genotoxic therapies is a primary cause of treatment failure and tumor recurrence. The underlying mechanisms that activate the DNA damage response (DDR) and allow cancer cells to escape...
17.
Sizemore G, Balakrishnan S, Thies K, Hammer A, Sizemore S, Trimboli A, et al.
Nat Commun
. 2018 Jul;
9(1):2783.
PMID: 30018330
The importance of the tumor-associated stroma in cancer progression is clear. However, it remains uncertain whether early events in the stroma are capable of initiating breast tumorigenesis. Here, we show...
18.
Sizemore S, Mohammad R, Sizemore G, Nowsheen S, Yu H, Ostrowski M, et al.
Mol Cancer Res
. 2018 Mar;
16(7):1092-1102.
PMID: 29592899
PARP inhibitors (PARPi) are potentially effective therapeutic agents capable of inducing synthetic lethality in tumors with deficiencies in homologous recombination (HR)-mediated DNA repair such as those carrying BRCA1 mutations. However,...
19.
Sahni J, Gayle S, Webb B, Weber-Bonk K, Seachrist D, Singh S, et al.
Cancer Res
. 2017 Aug;
77(19):5395-5408.
PMID: 28807940
Triple-negative breast cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies, and frequently recur, making the discovery of novel therapeutic targets for this disease imperative. Our previous analysis of the...
20.
Seachrist D, Sizemore S, Johnson E, Abdul-Karim F, Bonk K, Keri R
Breast Cancer Res
. 2017 Jun;
19(1):66.
PMID: 28583174
Background: Follistatin (FST) is an intrinsic inhibitor of activin, a member of the transforming growth factor-β superfamily of ligands. The prognostic value of FST and its family members, the follistatin-like...